An Open-label Study of Excretion Balance and Pharmacokinetics Following a Single Oral Dose of [14C]-Sodium Valproate (3.7 MBq) in Healthy Postmenopausal or Permanently Sterile Female Subjects
Phase of Trial: Phase I
Latest Information Update: 24 May 2019
Price : $35 *
At a glance
- Drugs Sodium valproate (Primary)
- Indications Epilepsy
- Focus Pharmacokinetics
- Sponsors Sanofi
- 21 May 2019 Status changed from active, no longer recruiting to completed.
- 22 Jan 2019 Planned End Date changed from 1 Jan 2019 to 1 Feb 2019.
- 22 Jan 2019 Planned primary completion date changed from 1 Jan 2019 to 1 Feb 2019.